Core Insights - Shanghai Rendu Biotechnology Co., Ltd. has released a semi-annual evaluation report on its "Quality Improvement and Efficiency Enhancement Return" action plan, highlighting the successful development of a new technology platform called "Digital SAT + Fully Automated Equipment DigiNAT" [1] - The new platform demonstrates significant advantages in detection sensitivity, operational convenience, and detection speed compared to traditional digital PCR technology, offering a more efficient and precise RNA detection solution with broad application potential [1] - Rendu Biotechnology is advancing the application of the Digital SAT platform in urinary system tumor screening, particularly for prostate and bladder cancer urine tests, with notable research progress [1] - The company aims to leverage its technological advantages to penetrate the tumor screening field amid the ongoing global development of precision medicine and early screening technologies [1]